Cardiol Therapeutics Inc. Class A CRDL 深 滬
等待開盤 07-22 09:30:00 美东时间
1.24
+0.005
+0.40%
華盛通- 最 高1.30
- 今 開1.24
- 成交量 73.20万股
- 最 低 1.22
- 昨 收 1.235
- 總市值 14.29万
- 52周最高 1.71
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 0.88
- 委 比 8.76%
- 總股本 0.00亿
- 歷史最高 4.96
- 量 比 0.43
- 振 幅 6.48%
- 歷史最低 0.45
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
07-15 01:22
Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
04-01 19:32
Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
02-10 20:30
Cardiol Therapeutics Surpasses 50% Participant Enrollment In MAVERIC Phase III Study Of CardiolRx
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
01-13 20:31
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute
2025-12-01 20:32
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last
2025-11-14 06:35
Cardiol Therapeutics Receives USPTO Notice Of Allowance For Patent On Cannabidiol Heart Therapies
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property
2025-11-13 20:49
Cardiol Therapeutics Secures $11M Financing, Advances Heart Disease Therapies
The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardi...
2025-10-18 05:06
